— 01 · At a Glance
What is PRRT?
★ In one paragraph
Peptide Receptor Radionuclide Therapy is a targeted radioligand treatment for neuroendocrine tumours. A peptide (DOTATATE) binds to somatostatin receptors on tumour cells, while its radioactive payload (Lu‑177) delivers beta radiation directly into the cancer — sparing healthy tissue. Administered as four outpatient cycles, eight weeks apart.
PRRT is the standard of care for somatostatin-receptor-positive neuroendocrine tumours (NETs) that have progressed despite somatostatin analogue therapy — agents like octreotide or lanreotide. It is not chemotherapy and it is not immunotherapy. It is a precision tool: the same biological target that lights up on a 68Ga-DOTATATE PET scan is the target the therapy binds to. If the scan shows the disease, the therapy can treat it.
At Theranostic Physicians, PRRT has been administered routinely since 2018 — with a current cadence of cycles every other Friday at our day-care suite at FMRI Sector 44, Gurugram. Patients are typically discharged within 6 hours of infusion.
— 02 · Mechanism
How PRRT works.
Neuroendocrine tumours overexpress somatostatin receptors — particularly SSTR2 and SSTR5 — on their cell surface. PRRT exploits that biology in three steps:
- Targeting. DOTATATE is a synthetic analogue of somatostatin. It binds selectively to SSTR receptors with high affinity — the same receptors that are visualised on a 68Ga-DOTATATE PET/CT scan.
- Delivery. The DOTATATE peptide is chemically chelated to Lutetium-177, a beta-emitting radioisotope with a 6.7-day half-life and a tissue range of approximately 2 mm.
- Cytotoxicity. Once bound and internalised by the tumour cell, the Lu-177 emits beta radiation that damages cellular DNA — primarily through double-strand breaks — leading to apoptosis. The 2 mm range means radiation crosses several cell diameters, treating microscopic disease in the vicinity of receptor-positive cells while sparing distant healthy tissue.
Because of the receptor specificity, off-target dosing is low. The main physiological sites of uptake are the spleen, kidneys, liver, and pituitary — which is why kidney protection and dosimetry monitoring are central to safe administration.
— 03 · Eligibility
Who is a candidate?
PRRT is most effective in well-selected patients. The decision is built on imaging, pathology, organ function and prior treatment lines. The standard eligibility criteria at our centre:
- Histologically confirmed well-differentiated neuroendocrine tumour, typically grade 1 or 2 (Ki-67 generally <20%).
- Somatostatin-receptor-positive disease demonstrated on a 68Ga-DOTATATE PET/CT (or DOTANOC/DOTATOC equivalents). Uptake should be greater than physiological liver uptake on the Krenning scale.
- Progressive disease on or after at least one line of somatostatin analogue therapy (octreotide LAR or lanreotide).
- Adequate organ function: creatinine clearance generally >50 mL/min, haemoglobin >8 g/dL, platelets >75 × 10⁹/L, total bilirubin <3× upper limit.
- Life expectancy of at least 6 months and ECOG performance status 0–2.
Common primary sites we treat: midgut (small intestinal) NETs, pancreatic NETs, bronchopulmonary carcinoid tumours, and rectal NETs. Less common but treatable: pheochromocytoma and paraganglioma with SSTR-positive disease, gastric NETs, and certain medullary thyroid cancers.
★ Important nuance
Grade 3 NETs and well-differentiated NETs with high Ki-67 require a more individualised conversation. PRRT can still benefit selected patients — particularly those with strong DOTATATE-PET uptake — but the response rates are lower and the case for combination or sequencing strategies becomes stronger. We discuss this candidly during the consultation.
— 04 · Protocol
The four-cycle protocol.
Standard PRRT at our centre follows the protocol established in the NETTER-1 phase 3 trial and recommended by the European Neuroendocrine Tumour Society (ENETS) and the Society of Nuclear Medicine & Molecular Imaging (SNMMI). Four cycles, eight weeks apart, with rigorous safety monitoring between each.
01
Pre-treatment work-up
68Ga-DOTATATE PET, baseline bloods (CBC, LFT, RFT, chromogranin-A), urinalysis. Octreotide is held for 4–6 weeks if applicable. We review prior imaging and pathology.
02
Cycle day — outpatient
30-minute Lu-177 DOTATATE infusion, preceded and accompanied by amino-acid co-infusion (lysine + arginine) over ~4 hours for renal protection. Antiemetics throughout.
03
24-hour SPECT/CT
Post-therapy imaging the next day to confirm tracer uptake in known disease and assess radiation distribution. Performed for every cycle.
04
Interim review
Bloods every 2–4 weeks. Interim DOTATATE-PET typically after cycles 2 and 4 to assess response. Decisions about continuation, escalation, or pause are made at these reviews.
Total course duration: approximately 7 to 8 months. Most patients are discharged the same day of each cycle. International patients typically need to be present in Gurugram for 48–72 hours per cycle.
— 05 · Evidence
Outcomes and trial data.
The evidence base for PRRT is among the strongest in nuclear oncology, anchored by two prospective randomised phase 3 trials.
NETTER-1 — the landmark trial
NETTER-11 randomised 229 patients with advanced, progressive midgut neuroendocrine tumours to either Lu-177 DOTATATE plus low-dose octreotide, or high-dose octreotide alone (60 mg long-acting). The results, published in the New England Journal of Medicine, were practice-changing:
79%
PFS at 20 months with PRRT
11%
PFS at 20 months with control
0.21
Hazard ratio for progression
Median progression-free survival in the PRRT arm was approximately 28.4 months versus 8.4 months for high-dose octreotide. The objective response rate by RECIST was 18% with PRRT, versus 3% in the control arm. Long-term follow-up data published in 2021 confirmed a sustained survival benefit.
NETTER-2 — first-line in higher-grade disease
The NETTER-22 trial, published in the Lancet in 2024, extended PRRT into the first-line setting for higher-grade (Grade 2 and Grade 3) GEP-NETs. The trial showed a median PFS of approximately 22.8 months with PRRT plus octreotide versus 8.5 months with high-dose octreotide alone — a hazard ratio of 0.276. This data supports earlier introduction of PRRT in well-selected patients with higher-proliferation NETs.
Indian real-world experience
Published Indian cohorts — including from our institution and other major Indian centres — report disease control rates of 70–85% and objective response rates broadly consistent with NETTER-1 findings. Bone-dominant disease, large hepatic tumour burden, and prior multiple chemotherapy lines are consistently associated with lower response.
— 06 · Pricing
Cost of PRRT in India.
We publish pricing in the open — in both INR and USD — because aggregators won't. The numbers below cover the therapy itself. Diagnostic imaging, inpatient room category, and concomitant medication are billed separately by FMRI.
| Variant |
Per cycle |
4-cycle course |
|
177Lu DOTATATE (international patient)
|
₹ 5,70,000
USD 6,333 |
₹ 22,80,000
USD 25,300 |
|
177Lu DOTATATE (Indian patient)
|
On request — calibrated case-by-case |
On request |
|
225Ac α-PRRT (international — salvage)
|
₹ 15,22,500
USD 16,917 |
Variable (typically 3–4 cycles) |
★ Please read
Figures are indicative ranges, not quotes. They cover the therapy fee at 1 USD = ₹ 90 and exclude 68Ga-DOTATATE PET imaging, post-therapy SPECT, inpatient stay, concomitant medication, and any FMRI hospital charges. A formal written quote is issued after pre-treatment evaluation and is honoured for 60 days.
Several major Indian insurers now cover Lu-177 DOTATATE for progressive somatostatin-receptor-positive NETs. Our coordinators help prepare the clinical documentation insurers typically require — WhatsApp us for a pre-authorisation pack.
For the deeper cost analysis — including a comparison with international centres — see our blog post on the cost of Lu-177 therapy in India.
— 07 · Tolerability
What about side effects?
PRRT is among the better-tolerated systemic cancer therapies in modern oncology. Most side effects are mild, transient, and manageable on the day of the cycle. Serious toxicities are uncommon and largely preventable with current protocols.
Common (>10% of patients)
- Nausea and vomiting — almost always mild, related to the amino-acid co-infusion, and resolves within 24 hours. Aggressively pre-medicated with anti-emetics.
- Fatigue — mild to moderate, typically lasting 1–2 weeks after each cycle.
- Lymphocytopenia — transient reduction in lymphocyte counts. Rarely requires intervention.
- Hormone-mediated symptoms in functional tumours — flushing, diarrhoea. Managed with continued short-acting octreotide.
Uncommon (1–10%)
- Mild anaemia and thrombocytopenia — monitored between cycles; doses may be delayed or reduced.
- Transient elevations in liver enzymes — especially with large hepatic burden.
Rare but serious
- Renal dysfunction — the kidneys are a dose-limiting organ. Amino-acid co-infusion, dosimetry monitoring, and creatinine clearance assessment before each cycle reduce this risk to less than 2%.
- Myelodysplastic syndrome / acute leukaemia — reported in <2% in long-term follow-up, often in patients with prior alkylating chemotherapy.
- Carcinoid crisis — in functional tumours. Prevented with perioperative octreotide infusion.
— 08 · Sequencing
When to consider Ac-225 PRRT.
After completion of 4 cycles of Lu-177 DOTATATE, approximately 70–80% of patients show disease control. For the subset who progress — or who present with bulky liver-dominant disease where deeper tissue penetration is needed — Ac-225 alpha-PRRT is the salvage option.
Alpha particles from Ac-225 have a tissue range of 50–100 micrometers — about 100 times shorter than Lu-177's beta range — but they deliver dramatically higher linear energy transfer (LET). The radiobiological effect per disintegration is 5–10× greater than beta radiation. This makes alpha-PRRT particularly useful for:
- Patients who have progressed on Lu-177 DOTATATE but retain strong DOTATATE-PET uptake.
- Bulky hepatic metastases where beta range is insufficient.
- Bone-marrow-protective sequencing in patients with marginal counts.
Learn more on our Ac-225 α-PRRT page or discuss escalation at your cycle 4 review.
— 09 · Availability
Next available PRRT slots.
PRRT at our centre is scheduled on alternate Fridays. Each cycle is an outpatient day — reach the centre by 8 a.m., discharged by 4 p.m. International patients typically combine the cycle with a 2–3 night stay in Gurugram.
PRRT calendar — next six weeks.
Frequently asked questions.
At Theranostic Physicians, Lu-177 DOTATATE PRRT for international patients is approximately ₹ 5,70,000 (USD 6,333) per cycle. A typical course of 4 cycles totals approximately ₹ 22,80,000 (USD 25,300).
Indian-patient pricing is calibrated case-by-case and provided in writing within 24 working hours. Pricing covers the therapy itself — diagnostic imaging, inpatient stay and concomitant medication are billed separately by FMRI.
In the phase 3 NETTER-1 trial, Lu-177 DOTATATE achieved a 79% progression-free survival at 20 months compared to 11% with high-dose octreotide alone. Median PFS was 28.4 months versus 8.4 months. Objective tumour response by RECIST was 18%.
Real-world Indian cohorts — including ours — report disease control rates of 70–85% and response rates broadly consistent with NETTER-1.
10-year survival for well-differentiated grade 1–2 NETs ranges from approximately 60% to 85% depending on primary site, grade, and metastatic status. With effective therapy including PRRT, surgery, and somatostatin analogues, many patients with metastatic NETs live for years or decades.
Outcomes are substantially better than for most other metastatic cancers — NETs are typically slow-growing and highly responsive to targeted radioligand therapy.
PRRT is for patients with somatostatin-receptor-positive neuroendocrine tumours, confirmed on a 68Ga-DOTATATE PET scan. Typical candidates have well-differentiated grade 1 to 2 NETs of gastroenteropancreatic or bronchopulmonary origin, with progressive disease despite somatostatin analogue therapy.
Adequate kidney, liver and bone marrow function are required. We assess each candidate individually during the consultation.
The standard protocol is 4 cycles of Lu-177 DOTATATE at 7.4 GBq each, every 8 weeks — totalling 7 to 8 months of treatment.
Cycle decisions are individualised based on tumour response on interim DOTATATE-PET, chromogranin-A kinetics, kidney function, and tolerability. Additional salvage cycles may be considered after disease progression.
Chemotherapy acts on all rapidly dividing cells, including healthy bone marrow, gut lining and hair follicles. PRRT delivers radiation only to cells expressing somatostatin receptors.
As a result, PRRT has substantially fewer systemic side effects, no hair loss, no severe nausea, and is given as a 30 to 45 minute outpatient infusion every 8 weeks. For most well-differentiated NETs, PRRT outperforms chemotherapy on both efficacy and tolerability.
Ac-225 alpha PRRT is typically considered after disease progression on Lu-177 DOTATATE, or for patients with bulky liver-dominant disease where alpha radiation's higher linear energy transfer is clinically advantageous.
The decision is individualised based on prior response, disease pattern, and dosimetry. We discuss escalation at the cycle 4 review.
Coverage is improving. Several major Indian private insurers now cover Lu-177 DOTATATE PRRT as an established therapy for progressive somatostatin-receptor-positive NETs, particularly when prior somatostatin analogue therapy has been tried.
Coverage varies by insurer and policy. Our coordinators help patients prepare the clinical documentation insurers typically require — please WhatsApp us for a pre-authorisation pack.
Most common: mild nausea on the day of treatment (well-managed with anti-emetics), transient fatigue lasting 1–2 weeks, and mild reductions in lymphocyte counts.
Rare but serious: kidney injury (mitigated by amino acid co-infusion), carcinoid crisis in functional tumours (prevented by perioperative octreotide), and bone marrow suppression in <5%. The overall safety profile is significantly better than chemotherapy for NETs.
Written & Medically Reviewed By
Dr. Ishita B. Sen
MBBS · DRM · DNB (Nuclear Medicine) · 30+ years in nuclear oncology
Director and Head, Department of Nuclear Medicine and Molecular Imaging, Fortis Memorial Research Institute. Visiting fellowships at Memorial Sloan Kettering Cancer Center, New York and University of Marburg, Germany. Past President, Association of Nuclear Medicine Physicians of India. Co-author on published Indian protocols for Lu-177 and Ac-225 therapy.
FellowshipsMSK New York · Marburg
Past PresidentANMPI
SpecialityTheranostics & PSMA / DOTATATE Therapy
Full profile
References & citations
- Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017;376:125–135. DOI: 10.1056/NEJMoa1607427 — the NETTER-1 trial.
- Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet, 2024;403:2807–2817.
- Strosberg J, Caplin ME, Kunz PL, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology, 2021;22(12):1752–1763.
- Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines. Annals of Oncology, 2020;31(7):844–860.
- Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology, 2017;105(3):295–309.
- Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al. 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide. Journal of Clinical Oncology, 2010;28(10):1652–1659.